Pros and cons of different therapeutic antibody formats for recombinant antivenom development

Research output: Contribution to journalJournal article – Annual report year: 2018Researchpeer-review

Standard

Pros and cons of different therapeutic antibody formats for recombinant antivenom development. / Laustsen, Andreas H.; Gutiérrez, José María; Knudsen, Cecilie; Johansen, Kristoffer H. ; Bermúdez-Méndez, Erick ; Cerni, Felipe A. ; Jürgensen, Jonas A. ; Ledsgaard, Line ; Martos Esteban, Andrea; Øhlenschlæger, Mia ; Pus, Urska; Andersen, Mikael R.; Lomonte, Bruno; Engmark, Mikael; Pucca, Manuela B. .

In: Toxicon, Vol. 146, 2018, p. 151-175.

Research output: Contribution to journalJournal article – Annual report year: 2018Researchpeer-review

Harvard

Laustsen, AH, Gutiérrez, JM, Knudsen, C, Johansen, KH, Bermúdez-Méndez, E, Cerni, FA, Jürgensen, JA, Ledsgaard, L, Martos Esteban, A, Øhlenschlæger, M, Pus, U, Andersen, MR, Lomonte, B, Engmark, M & Pucca, MB 2018, 'Pros and cons of different therapeutic antibody formats for recombinant antivenom development', Toxicon, vol. 146, pp. 151-175. https://doi.org/10.1016/j.toxicon.2018.03.004

APA

Laustsen, A. H., Gutiérrez, J. M., Knudsen, C., Johansen, K. H., Bermúdez-Méndez, E., Cerni, F. A., ... Pucca, M. B. (2018). Pros and cons of different therapeutic antibody formats for recombinant antivenom development. Toxicon, 146, 151-175. https://doi.org/10.1016/j.toxicon.2018.03.004

CBE

Laustsen AH, Gutiérrez JM, Knudsen C, Johansen KH, Bermúdez-Méndez E, Cerni FA, Jürgensen JA, Ledsgaard L, Martos Esteban A, Øhlenschlæger M, Pus U, Andersen MR, Lomonte B, Engmark M, Pucca MB. 2018. Pros and cons of different therapeutic antibody formats for recombinant antivenom development. Toxicon. 146:151-175. https://doi.org/10.1016/j.toxicon.2018.03.004

MLA

Vancouver

Author

Laustsen, Andreas H. ; Gutiérrez, José María ; Knudsen, Cecilie ; Johansen, Kristoffer H. ; Bermúdez-Méndez, Erick ; Cerni, Felipe A. ; Jürgensen, Jonas A. ; Ledsgaard, Line ; Martos Esteban, Andrea ; Øhlenschlæger, Mia ; Pus, Urska ; Andersen, Mikael R. ; Lomonte, Bruno ; Engmark, Mikael ; Pucca, Manuela B. . / Pros and cons of different therapeutic antibody formats for recombinant antivenom development. In: Toxicon. 2018 ; Vol. 146. pp. 151-175.

Bibtex

@article{4d85d4d6d3ac47f78fceb9a3aa8ee9c8,
title = "Pros and cons of different therapeutic antibody formats for recombinant antivenom development",
abstract = "Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many advances in immunology, synthetic biology, and antibody research, different approaches and antibody formats are being investigated for the ability to neutralize animal toxins. These different molecular formats each have their own therapeutic characteristics. In this review, we provide an overview of the advances made in the development of toxin-targeting antibodies, and discuss the benefits and drawbacks of different antibody formats in relation to their ability to neutralize toxins, pharmacokinetic features, propensity to cause adverse reactions, formulation, and expression for research and development (R&D) purposes and large-scale manufacturing. A research trend seems to be emerging towards the use of human antibody formats as well as camelid heavy-domain antibody fragments due to their compatibility with the human immune system, beneficial therapeutic properties, and the ability to manufacture these molecules cost-effectively.  ",
keywords = "Antivenom, Venom, Recombinant antivenom, Antibodies, Snakebite, Scorpion sting, Spider bite, Animal envenoming, Pharmacokinetics, Pharmacodynamics, Immunogenicity, Venom neutralization, Antibody expression, Antivenom design, Adverse reactions, Neglected tropical diseases, Biotechnology",
author = "Laustsen, {Andreas H.} and Guti{\'e}rrez, {Jos{\'e} Mar{\'i}a} and Cecilie Knudsen and Johansen, {Kristoffer H.} and Erick Berm{\'u}dez-M{\'e}ndez and Cerni, {Felipe A.} and J{\"u}rgensen, {Jonas A.} and Line Ledsgaard and {Martos Esteban}, Andrea and Mia {\O}hlenschl{\ae}ger and Urska Pus and Andersen, {Mikael R.} and Bruno Lomonte and Mikael Engmark and Pucca, {Manuela B.}",
year = "2018",
doi = "10.1016/j.toxicon.2018.03.004",
language = "English",
volume = "146",
pages = "151--175",
journal = "Toxicon",
issn = "0041-0101",
publisher = "Pergamon Press",

}

RIS

TY - JOUR

T1 - Pros and cons of different therapeutic antibody formats for recombinant antivenom development

AU - Laustsen, Andreas H.

AU - Gutiérrez, José María

AU - Knudsen, Cecilie

AU - Johansen, Kristoffer H.

AU - Bermúdez-Méndez, Erick

AU - Cerni, Felipe A.

AU - Jürgensen, Jonas A.

AU - Ledsgaard, Line

AU - Martos Esteban, Andrea

AU - Øhlenschlæger, Mia

AU - Pus, Urska

AU - Andersen, Mikael R.

AU - Lomonte, Bruno

AU - Engmark, Mikael

AU - Pucca, Manuela B.

PY - 2018

Y1 - 2018

N2 - Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many advances in immunology, synthetic biology, and antibody research, different approaches and antibody formats are being investigated for the ability to neutralize animal toxins. These different molecular formats each have their own therapeutic characteristics. In this review, we provide an overview of the advances made in the development of toxin-targeting antibodies, and discuss the benefits and drawbacks of different antibody formats in relation to their ability to neutralize toxins, pharmacokinetic features, propensity to cause adverse reactions, formulation, and expression for research and development (R&D) purposes and large-scale manufacturing. A research trend seems to be emerging towards the use of human antibody formats as well as camelid heavy-domain antibody fragments due to their compatibility with the human immune system, beneficial therapeutic properties, and the ability to manufacture these molecules cost-effectively.  

AB - Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many advances in immunology, synthetic biology, and antibody research, different approaches and antibody formats are being investigated for the ability to neutralize animal toxins. These different molecular formats each have their own therapeutic characteristics. In this review, we provide an overview of the advances made in the development of toxin-targeting antibodies, and discuss the benefits and drawbacks of different antibody formats in relation to their ability to neutralize toxins, pharmacokinetic features, propensity to cause adverse reactions, formulation, and expression for research and development (R&D) purposes and large-scale manufacturing. A research trend seems to be emerging towards the use of human antibody formats as well as camelid heavy-domain antibody fragments due to their compatibility with the human immune system, beneficial therapeutic properties, and the ability to manufacture these molecules cost-effectively.  

KW - Antivenom

KW - Venom

KW - Recombinant antivenom

KW - Antibodies

KW - Snakebite

KW - Scorpion sting

KW - Spider bite

KW - Animal envenoming

KW - Pharmacokinetics

KW - Pharmacodynamics

KW - Immunogenicity

KW - Venom neutralization

KW - Antibody expression

KW - Antivenom design

KW - Adverse reactions

KW - Neglected tropical diseases

KW - Biotechnology

U2 - 10.1016/j.toxicon.2018.03.004

DO - 10.1016/j.toxicon.2018.03.004

M3 - Journal article

VL - 146

SP - 151

EP - 175

JO - Toxicon

JF - Toxicon

SN - 0041-0101

ER -